Research towards the development of ion channel modulators is booming. One exciting target is the Kv1.3 voltage activated potassium channel. Expressed by human T lymphocytes Kv1.3 is involved in proliferation and cytokine secretion. Animal studies have established Kv1.3 as a target for the unmet multiple sclerosis (MS) market. Further key proof of concept data has now emerged demonstrating the selective expression of this channel in myelin-reactive effector memory T cells from MS patients
Pharma NewsBytes is LeadDiscovery's summary of news items released from the pharmaceutical and biotech sector over the previous two weeks. This week we feature the FDA's backing of the statin, Crestor; a new agreement based on the development of HDAC inhibitors which could leed to imporved cancer therapeutics; a novel and highly promising approach to metabolic disease announced by Roche; emerging clinical data on what appears to be an effective treatment of primary liver cancer and more.....
Although elderly people have a higher incidence of the four major cancers than any other age group, there is a fundamental lack of knowledge regarding the treatment of this demographic, resulting in their under-treatment. Commercial opportunity therefore awaits any pharmaceutical company able to target the development of strategies aimed specifically at elderly patients.
Faced with rising costs, shortened product lifecycles and an increasing reliance on blockbuster drugs, pharmaceutical companies are turning towards innovative marketing campaigns and new channels to reach an increasingly demanding consumer audience. Offering particular potential, campaign management solutions are being introduced to establish profitable interactions with large numbers of consumers across multiple channels.
The pharmaceutical industry is currently sinking considerable resources into the treatment of autoimmune disorders. One new candidate target is the histone deacetylase, HDAC7, reviewed in LeadDiscoveryâ€™s Target of the Month for July. HDAC7 inhibits Nur77 expression, a key regulator of T cell receptor mediated T cell apoptosis. Blocking HDAC7 can potentialy enhance apoptosis of autoreactive T cells and HDAC7 inhibitors may therefore be candidate treatments of autoimmune disorders.
Biogen and Idec Pharmaceuticals are set to merge in a stock-for-stock transaction valued at over $6.6 billion following announcements made earlier this week. The deal will create the third largest biotech firm in the world, yet Wall Street has so far appeared unimpressed by the deal. Even individual analysts seem to be disagreeing as to the strategic sense of the partnership.
At every stage of the R&D process, the companies must evaluate the time, logistics, expense and expertise that they can allocate. This also entails knowing when to rely on in-house capabilities and wh
Dr Faiz Kermani
Uncontrolled proliferation is a common feature of malignant cells. Proliferation correlates with a nuclear protein known as Ki-67. Researchers have now shown that an antisense oligonucleotide against
To mark the American Society of Clinical Oncology's 2003 conference, LeadDiscovery has launched The Oncology Collection. The Oncology Collection groups all of LeadDiscovery's oncology services in one
Statins have become the gold standard in the treatment of dyslipidemia, accounting for approximately 60% of treatments prescribed to patients with coronary heart disease in the late 1990s. However, wi
Eli Lilly and Company is set to launch Cymbalta into the depression and stress urinary incontinence markets in mid-2003. Datamonitor analyzes whether the company most synonymous with the antidepressan
Switzerland has been a major force in the development of new medicines for over a century. Around 5% of current global pharmaceutical R&D is attributable to Swiss companies.
Larry Hughes and Dr Faiz Kermani
The healthcare industry has utilized the Internet most recently as both a marketing tool and as a facility to pass on important medical information. Leading drug maker Abbott Laboratories will be look
Over the past decade, behavioral disorders have received increasing attention, both from the media and medical professionals, however only attention deficit/hyperactivity disorder has emerged as a key
Enterprise Incentive Management (EIM) software -improves pharmaceutical sales and provides accurate and timely compensation to both direct and indirect sales people. Already used in the pharmaceutica
The development of novel medicines is critical if diseases and disorders are to be effectively treated. As a result, many have looked to biotechnology to provide continuing innovation in the field of
Pietro Bonacossa and Dr Faiz Kermani
Investing in R&D requires long-term planning and the willingness to take risks. Only about 15% of new drugs entering development subsequently reach the market, and the overall expense can be in the or
Faiz Kermaini & Pietro Bonacossa
Asthma drives a large but competitive market. Current therapeutics are generally effective but patient compliance is often poor. Future commercial successes in the asthma arena will likely focus on mo
LeadDiscovery/Prof. Peter Barnes
Roche's recent announcement of an EU price point of $20,570 per year for its novel HIV fusion inhibitor Fuzeon has brought the issue of pricing HIV therapies to the fore. Roche's premium pricing strat
Approximately 9% of the US population suffers from moderate to severe non-cancer-related pain, a figure that includes 40-70 million individuals with chronic pain. The development of analgesics represe
Considerable evidence exists linking the retinoids to amyloid expression and neural responses to amyloid. Retinoic acid derivative may thus offer a therapeutic avenue for Alzheimer's disease
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her